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Abstract
Objective—HIV-infected people have greatly elevated risk of non-Hodgkin lymphoma (NHL), 
particularly the AIDS-defining NHL subtypes: diffuse large B-cell lymphoma, Burkitt lymphoma 
and primary lymphomas arising in the central nervous system. The goals of this analysis were to 
comprehensively describe risks of NHL subtypes, especially those not well studied, among HIV/
AIDS patients; examine risks specifically in the HAART era; and distinguish risks in HIV-
infected individuals prior to diagnosis with AIDS.
Design—Population-based registry linkage study.
Methods—We used data from the US HIV/AIDS Cancer Match Study from 1996 to 2010 (N = 
273 705) to calculate standardized incidence ratios (SIRs) comparing subtype specific NHL risks 
in HIV-infected people to those in the general population, and used Poisson regression to test for 
differences in SIRs between the HIV-only and AIDS periods.
Results—NHL risk was elevated 11-fold compared to the general population, but varied 
substantially by subtype. AIDS-defining NHL subtypes comprised the majority, and risks were 
high (SIRs ≥ 17), but risks were also increased for some T-cell lymphomas (SIRs = 3.6–14.2), 
marginal zone lymphoma (SIR = 2.4), lymphoplasmacytic lymphoma/Waldenström 
macroglobulinemia (SIR = 3.6), and acute lymphoblastic leuke mia/lymphoma (SIR = 2.4).
Conclusion—HIV-infected people in the HAART era continue to have elevated risk of AIDS-
defining NHL subtypes, highlighting the contribution of moderate and severe immunosuppression 
to their cause. Whereas non-AIDS-defining subtypes are much less common, immunosuppression 
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or other dysregulated immune states likely play a role in the cause of some T-cell lymphomas, 
marginal zone lymphoma, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, and 
acute lymphoblastic leukemia/lym phoma.
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Introduction
HIV infection causes progressive immune impairment, potentially leading to AIDS. HIV-
infected people have greatly elevated risk of non-Hodgkin lymphoma (NHL), particularly 
subtypes classified as ‘AIDS-defining events’ [1]: diffuse large B-cell lymphoma (DLBCL), 
Burkitt lymphoma, and primary lymphomas of the central nervous system (CNS) [2,3]. 
However, HIV-associated risk for other NHL subtypes remains poorly understood.
Among HIV-infected people, widespread adoption of HAART beginning in 1996 has 
improved HIV-related immunodeficiency and decreased overall NHL incidence [4,5]. 
Characterizing risk of specific AIDS-defining and non-AIDS-defining NHL subtypes in the 
HAART era can provide insights into the causative role of immunodeficiency across the 
spectrum of NHL subtypes.
Methods
We examined risk of NHL subtypes in HIV-infected people using population-based data 
from the HIV/AIDS Cancer Match (HACM) Study [3]. Briefly, HIV/AIDS and cancer 
registry data were linked in seven US states with name-based registration of HIV infection: 
Colorado (systematic registration starting in 1991), Connecticut (2002), Florida (1998), 
Georgia (2004), Michigan (1992), New Jersey (1992), and Texas (1997). Our analysis 
included 273 705 people registered with HIV infection without AIDS (i.e. HIV-only) or with 
AIDS and followed during 1996–2010 (N = 1 459 816 person-years). Incident NHL cases 
were identified from cancer registries, and NHL subtypes were classified using International 
Classification of Disease for Oncology (3rd edition, ICD-O3) topography and morphology 
codes (Supplemental Table 1, http://links.lww.com/QAD/A566). We also separately 
examined risk of primary CNS lymphoma regardless of histologic subtype. The HACM 
Study was approved by human patient committees at participating registries as required.
For the primary analysis, follow-up started at the later of HIV report (AIDS diagnosis if HIV 
was not reported earlier) or start of systematic HIV reporting to the registry. Follow-up 
ended at the earliest of NHL diagnosis, death, or end of cancer registry coverage. We 
conducted further analyses separately during the HIV-only versus AIDS intervals 
(representing lesser or greater degrees of immunosuppression, respectively). For AIDS-
defining NHL subtypes, the HIV-only analysis examined risk of NHL as an AIDS-defining 
event in those reported with HIV, whereas the AIDS analysis examined risk among people 
already diagnosed with AIDS based on another indication. Notably, incidence for the AIDS-
defining NHL subtypes was very high in the first 3 months after AIDS diagnosis, likely 
reflecting slight differences in diagnosis dates reported to the HIVand cancer registries. 
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Thus, we included the first 3 months after AIDS diagnosis in the HIV-only period. However, 
the comparisons of NHL subtype risks for the HIV-only versus AIDS intervals described 
below remained similar if cases in the first 3 months were instead counted in the AIDS 
period (data not shown). Because we did not have information on the at-risk HIV group until 
they were reported to the HIV registry, we did not include NHL cases where HIV report, 
AIDS diagnosis and NHL diagnosis occurred simultaneously (or NHL was diagnosed within 
3 months of both HIV and AIDS for AIDS-defining subtypes).
In each analysis, we compared risk in HIV-infected people to the general population using 
standardized incidence ratios (SIRs = observed cases/expected cases). Expected cases were 
derived by applying general population cancer rates from the registries to person-time at risk 
in the HIV-infected cohort, stratified by sex, age, race/ethnicity, calendar year, and registry. 
We used Poisson regression to test for differences in SIRs between the HIV-only and AIDS 
periods, and across calendar periods.
Results
Ninety percent of the 2828 cases of NHL diagnosed in the HIV-infected people were one of 
the AIDS-defining histologic subtypes [50% DLBCL, 9% Burkitt lymphoma, and 31% 
NHL-not otherwise specified (NOS); Table 1]. We included NHL-NOS as an AIDS-
defining subtype for presentation of results, because these likely comprised mostly DLBCL, 
and SIRs were similar for these two subtypes. Almost all CNS lymphomas were DLBCL 
(40%) or NHL-NOS (57%), but if other histologic subtypes arising in the CNS were 
included (N = 14), then 91% of NHLs were AIDS-defining subtypes (Table 1).
Risks were elevated 11-fold for NHL overall and at least 17-fold compared to the general 
population for all AIDS-defining subtypes (Table 1), with the greatest elevations observed 
for Burkitt lymphoma (SIR = 33.7) and CNS lymphoma (SIR = 47.7). Risks were 
significantly greater in the AIDS period compared to the HIV-only period for DLBCL, 
NHL-NOS and CNS lymphoma (P < 0.0001; Table 2). Notably, Burkitt lymphoma risk did 
not differ between the HIV-only and AIDS periods. SIRs were significantly lower during 
2003–2010 than 1996–2002 for DLBCL, CNS lymphomas and NHL-NOS, but not for 
Burkitt lymphoma (Supplemental Table 2, http://links.lww.com/QAD/A566).
All non-AIDS-defining subtypes combined comprised the remaining 10% of NHL cases. 
The most common subtypes were anaplastic large cell lymphoma (ALCL, N = 68), 
peripheral T-cell lymphoma (PTCL, N = 39), and follicular lymphoma (N = 44).
Among the non-AIDS-defining subtypes, risks relative to the general population were 
elevated for ALCL (SIR = 14.2), natural killer (NK)/T-cell lymphoma (SIR = 3.9), PTCL 
(SIR = 3.6), lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia (SIR = 
3.6), marginal zone lymphoma (SIR = 2.4), and acute lymphoblastic leukemia/lymphoma 
(ALL; SIR = 2.4; Table 1). In contrast, risk was not significantly different from the general 
population for follicular lymphoma, chronic lymphocytic leukemia (CLL)/small 
lymphocytic lymphoma (SLL), mantle cell lymphoma, mycosis fungoides/Sézary syndrome, 
or other rarer NHL subtypes. Risks of ALCL and PTCL were significantly greater in the 
Gibson et al. Page 3













AIDS period compared to the HIV-only period (P = 0.0003 and 0.03, respectively), whereas 
there was no difference by AIDS status for NK/T-cell lymphoma, LPL/Waldenström 
macroglobulinemia, marginal zone lymphoma, or ALL (Table 2). SIRs were lower for all 
non-AIDS-defining subtypes during 2003–2010 than 1996–2002, though the differences by 
time period were statistically significant only for ALCL and CLL/SLL (Supplemental Table 
2, http://links.lww.com/QAD/A566).
Discussion
Non-Hodgkin lymphoma risk in HIV-infected people in developed countries has diminished 
with widespread use and effectiveness of HAART [4,5]. Nonetheless, our results 
demonstrate that risk remains greatly elevated relative to the general population, even 
among the growing fraction of the population infected with HIV, but not diagnosed with 
AIDS. While NHL has often been considered as a single cancer entity for studies of HIV-
infected people, we provide the first comprehensive evidence of substantial heterogeneity in 
HIV-related risks for distinct NHL subtypes.
The considerable elevation in risk for AIDS-defining NHL subtypes in the HAART era is 
consistent with previous studies [3,5] and the increased risk in those with AIDS compared to 
those with HIV-only supports severity of immune deficiency as a primary determinant of 
risk for these subtypes. Among HIV-infected people, loss of immune control of Epstein–
Barr virus (EBV) is key to the cause of CNS lymphoma and DLBCL [6]. For DLBCL and 
CNS lymphomas, the magnitude of risk and the differences between the HIV-only and 
AIDS intervals that we observed were somewhat smaller than reported previously [3,5], 
possibly due to our inclusion of more recent follow-up time with improved HIV therapy. 
Indeed, risk of these subtypes decreased over time in our study, likely reflecting improved 
uptake and effectiveness of antiretroviral therapy [7]. Results for NHL-NOS were similar to 
those for DLBCL, suggesting the NHL-NOS category was comprised largely of unclassified 
DLBCL or cases of plasmablastic morphology that did not have specific ICD-O3 codes prior 
to 2008. Burkitt lymphoma risk was similar in people with HIV-only and AIDS and did not 
decrease over time, perhaps reflecting a somewhat complex relationship with degree of 
immunosuppression [8].
Although the AIDS-defining subtypes still comprise the vast majority of NHL cases, it is 
increasingly important to understand the risks of non-AIDS-defining cancers as people live 
longer with HIV. We found significantly elevated risk for several T-cell lymphoma subtypes 
(ALCL, PTCL, NK/T cell), extending previous findings among people with AIDS from the 
pre-HAARTera [9]. ALCL and PTCL risks were significantly higher in people with AIDS 
than with HIV-only, and ALCL risk declined over time, pointing to the importance of 
immunodeficiency in the cause of these subtypes.
The elevated risks we found for marginal zone lymphoma, LPL/Waldenström 
macroglobulinemia, and ALL support a role for HIV in the cause of these subtypes, but 
similar risks in people with HIV-only and AIDS suggest mechanisms other than immune 
deficiency. Chronic antigenic stimulation by persistent infection [e.g. with Helicobacter 
pylori, hepatitis C virus (HCV)], autoimmune disease, or blood transfusion has been 
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implicated in the cause of both marginal zone lymphoma and LPL/Waldenström 
macroglobulinemia [10–13]. Thus, the immune activation and inflammation associated with 
HIV infection may underlie the increased risks of these subtypes. An elevated prevalence of 
HCV infection among individuals with HIV may contribute to the elevated risk observed for 
marginal zone lymphoma, but evidence from prior studies indicates HCV may not be a risk 
factor for this NHL subtype in the context of immunosuppression [14–16]. We did not see 
an elevated risk for follicular lymphoma or CLL/SLL, in line with the previous results [17], 
suggesting that immune perturbation does not play a major role in development of these 
types of NHLs. The similarity of the NHL risk patterns in our results to those after solid 
organ transplantation [18] further argues for a key role for immunosuppression and other 
immune abnormalities in the cause of specific subtypes [19].
The primary strength of this analysis was the use of a large population-based HIV cohort 
with systematic ascertainment of NHL and characterization of subtypes by cancer registries. 
Our study extends previous findings by including more recent follow-up and by examining 
risks of specific non-AIDS-defining NHL subtypes. Several limitations should also be noted. 
We could not evaluate HAART use and CD4+ cell counts in relation to risk, as these data 
were inconsistently available. SIRs for the AIDS-defining NHL subtypes likely 
underestimate the relative risk because a substantial fraction of the cases in the general 
population may be attributable to HIV infection (e.g. 27% of Burkitt lymphoma and 8% of 
DLBCL) [20,21]. Additionally, numbers were limited for assessing the risks of rare NHL 
subtypes. Misclassification of NHL subtypes was possible (e.g. primary effusion lymphoma 
expressing aberrant T-cell antigens), and 90% of NHL cases in our analysis were diagnosed 
prior to 2008, so the results do not reflect the most recent changes in subtype classification. 
Finally, approximately 16% of people with HIV in the United States have undiagnosed 
infection [22], but we were only able to examine NHL risk in those with diagnosed HIV 
infection.
In conclusion, HIV-infected people in the HAART era continue to have elevated risk of 
NHL, and this risk varies substantially by subtype. Most NHLs are the AIDS-defining NHL 
subtypes, highlighting the strong contribution of immunosuppression and EBV to their 
cause. Although non-AIDS-defining subtypes are much less common, immunosuppression 
or other dysregulated immune states likely play a role for some T-cell lymphomas, marginal 
zone lymphoma, LPL/Walden-ström macroglobulinemia, and ALL. Additional research 
should address the detailed immune mechanisms underlying these observations.
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Table 1
Risk of non-Hodgkin lymphoma subtypes among people registered with HIV infection or AIDS in the United 
States (1996–2010).
NHL subtypes Cases (N) (%) Incidence rate
a SIR 95% CI
AIDS-defining
    DLBCL 1404 49.6 96.2 17.6 16.7–18.6
    Burkitt 262 9.3 17.9 33.7 29.7–38.0
    Central nervous system 464 16.4 31.8 47.7 43.4–52.2
    NHL-NOS 884 31.3 60.6 19.9 18.6–21.2
Non-AIDS-defining
    Follicular 44 1.6 3.0 1.3 1.0–1.8
    CLL/SLL 30 1.1 2.1 0.8 0.5–1.2
    Marginal zone 31 1.1 2.1 2.4 1.6–3.4
    Mantle cell 6 0.2 0.4 1.0 0.4–2.3
    LPL/WM 14 0.5 1.0 3.6 2.0–6.0
    ALCL 68 2.4 4.7 14.2 11.0–18.0
    Primary cutaneous ALCL 3 0.1 0.2 3.9 0.8–11.3
    Peripheral T cell 39 1.4 2.7 3.6 2.6–4.9
    MF/SS 5 0.2 0.3 0.8 0.3–1.8
    Natural killer/T cell 4 0.1 0.3 3.9 1.1–9.9
    ALL
b 27 1.0 1.8 2.4 1.6–3.4
    Other specified 7 0.2 0.5 1.1 0.4–2.2
    Overall NHL
c 2828 100 193.7 10.6 10.2–11.0
95% CI, 95% confidence interval; ALCL, anaplastic large cell lymphoma; ALL, acute lymphoblastic leukemia/lymphoma; CLL/SLL, chronic 
lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; LPL/WM, lymphoplasmacytic lymphoma/
Waldenström macroglobulinemia; MF/SS, mycosis fungoides/Sézary syndrome; NHL, non-Hodgkin lymphoma; NOS, not otherwise specified; 
SIR, standardized incidence ratio.
a
Cases per 100000 person-years.
b
Includes all precursor lymphoid neoplasms.
c
The number of overall NHL cases is the sum of the subtypes listed excluding central nervous system lymphomas, which are included in the 
appropriate histologic subtype categories.
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Table 2
Comparison of non-Hodgkin lymphoma risk during the HIV-only and AIDS periods.
HIV-only
a AIDS




    DLBCL 330 11.6 10.4–12.9 1074 20.9 19.7–22.2 <0.0001
    Burkitt 114 38.8 32.0–46.6 148 30.6 25.8–35.9 0.06
    Central nervous system 81 22.2 17.6–27.6 383 63.0 56.8–69.6 <0.0001
    NHL-NOS 203 13.1 11.3–15.0 681 23.5 21.7–25.3 <0.0001
Non-AIDS-defining
    Follicular 13 1.1 0.6–1.9 31 1.4 1.0–2.0 0.52
    CLL/SLL 11 0.9 0.5–1.6 19 0.8 0.5–1.2 0.63
    Marginal zone 16 3.5 2.0–5.7 15 1.8 1.0–3.0 0.06
    Mantle cell 0 0 0–2.0 6 1.6 0.6–3.4 –
    LPL/WM 4 3.1 0.8–7.8 10 3.9 1.8–7.1 0.70
    ALCL 10 5.7 2.7–10.4 58 19.2 14.6–24.9 0.0003
    Peripheral T cell 7 1.8 0.7–3.8 32 4.6 3.1–6.4 0.03
    MF/SS 2 0.8 0.1–3.1 3 0.7 0.2–2.2 0.89
    Natural killer/T cell 1 2.7 0.1–15.3 3 4.5 0.9–13.1 0.67
    ALL
c 12 2.7 1.4–4.7 15 2.2 1.2–3.6 0.59
    Other specified 2 0.9 0.1–3.2 5 1.2 0.4–2.8 0.71
Overall NHL
d 725 7.7 7.2–8.3 2103 12.1 11.6–12.7 <0.0001
95% CI, 95% confidence interval; ALCL, anaplastic large cell lymphoma; ALL, acute lymphoblastic leukemia/lymphoma; CLL/SLL, chronic 
lymphocytic leukemia/small lymphocytic lymphoma; CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma; LPL/WM, 
lymphoplasmacytic lymphoma/Waldenström macroglobulinemia; MF/SS, mycosis fungoides/Sézary syndrome; NHL, non-Hodgkin lymphoma; 
NOS, not otherwise specified; SIR, standardized incidence ratio. Note: HIV-Only = 583692 person-years; AIDS = 876124 person-years.
a
HIV-only period includes the first three months after AIDS diagnosis in those who also developed AIDS; for AIDS-defining subtypes, cases in 
the HIV-only period are comprised of NHLs that occurred as the AIDS-defining event.
b
Test for difference of SIRs in the HIV-only and AIDS periods, using Poisson regression models with sex and age.
c
Includes all precursor lymphoid neoplasms.
d
The number of overall NHL cases is the sum of the subtypes listed, excluding central nervous system lymphomas, which are included in the 
appropriate histologic subtype categories.
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